Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 37 citing articles:

Contemporary medical, device, and surgical therapies for obesity in adults
Carolina M. Perdomo, Ricardo V. Cohen, Priya Sumithran, et al.
The Lancet (2023) Vol. 401, Iss. 10382, pp. 1116-1130
Closed Access | Times Cited: 374
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 133
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cindy X. Cai, Michelle R. Hribar, Sally L. Baxter, et al.
JAMA Ophthalmology (2025)
Closed Access | Times Cited: 7
Diabetes and cognitive function: An evidence-based current perspective
Meghna Julian Sebastian, Shahanas K A Khan, Joseph M Pappachan, et al.
World Journal of Diabetes (2023) Vol. 14, Iss. 2, pp. 92-109
Open Access | Times Cited: 39
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Rafael Tamayo‐Trujillo, Viviana A. Ruiz‐Pozo, Santiago Cadena-Ullauri, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 14
Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study
Nabeela Siddeeque, Mohammad H. Hussein, Ahmed Abd‐Elmaksoud, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113537-113537
Open Access | Times Cited: 11
The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment
Haohui Sun, Yue Hao, Hao Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Xiaoyan Yang, Peng Feng, Rong Ji, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 5, pp. 445-460
Closed Access | Times Cited: 29
Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules
Nassima Oumata, Kui Lu, Yuou Teng, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114578-114578
Closed Access | Times Cited: 29
Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway
Mohamed A. Sadek, Esraa A. Kandil, Nesrine S. El Sayed, et al.
International Immunopharmacology (2022) Vol. 115, pp. 109647-109647
Closed Access | Times Cited: 26
Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry
Wilfredo López-Ojeda, Robin A. Hurley
Journal of Neuropsychiatry (2024) Vol. 36, Iss. 2, pp. A4-86
Closed Access | Times Cited: 6
Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development
Desh Deepak Singh, Ali A. Shati, Mohammad Y. Alfaifi, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3767-3767
Open Access | Times Cited: 20
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee, Rinkoo Dalan
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1386-1386
Open Access | Times Cited: 4
Cerebral Small Vessel Disease: Therapeutic Approaches Targeting Neuroinflammation, Oxidative Stress, and Endothelial Dysfunction
Habibe Yılmaz, Ulvi Bayraktutan
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 4, pp. 232-232
Open Access
Full-spectrum Cannabis sativa extract enhances gut-peripheral organ integrity after experimental ischemic stroke
Solange Stork, Khiany Mathias, Fernanda Gava, et al.
Inflammopharmacology (2025)
Closed Access
Neuroprotective effects of saxagliptin against radiation-induced cognitive impairment: Insights on Akt/CREB/SIRT1/BDNF signaling pathway
Ashrakt H. Abdelhamid, Eman M. Mantawy, Riham S. Said, et al.
Toxicology and Applied Pharmacology (2024) Vol. 489, pp. 116994-116994
Closed Access | Times Cited: 3
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
Maria Antonietta Riemma, Elena Mele, Maria Donniacuo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord
Sing-Ong Lee, Yaswanth Kuthati, Wei-Hsiu Huang, et al.
Cells (2024) Vol. 13, Iss. 22, pp. 1857-1857
Open Access | Times Cited: 3
Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?
David M. Williams, Michael Atkinson, Marc Evans
Stroke (2023) Vol. 54, Iss. 5, pp. 1441-1451
Closed Access | Times Cited: 8
The impact of GLP-1 signalling on the energy metabolism of pancreatic islet β-cells and extrapancreatic tissues
Leah A. Peart, Matthew Draper, Andrei I. Tarasov
Peptides (2024) Vol. 178, pp. 171243-171243
Closed Access | Times Cited: 2
Melatonin-mediated IGF-1/GLP-1 activation in experimental OCD rats: Evidence from CSF, blood plasma, brain and in-silico investigations
Aditi Giri, Sidharth Mehan, Zuber Khan, et al.
Biochemical Pharmacology (2023) Vol. 217, pp. 115831-115831
Closed Access | Times Cited: 6
Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study
Yu‐Chi Su, Pei-Chun Hsieh, Edward Chia‐Cheng Lai, et al.
Diabetes & Metabolism (2024) Vol. 50, Iss. 4, pp. 101545-101545
Closed Access | Times Cited: 2
Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i
А. В. Симаненкова, Oksana Fuks, Н. В. Тимкина, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 7
Open Access | Times Cited: 2
Designer GLP1 poly-agonist peptides in the management of diabesity
Laura Statham, Melina Pelling, Petra Hanson, et al.
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 3, pp. 231-240
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top